Texas Permanent School Fund Vir Biotechnology, Inc. Transaction History

Texas Permanent School Fund

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$7.63 - $12.66 $80,404 - $133,411	-10,538 Reduced 14.05%	64,439 $573,000
Q1 2024 May 03, 2024	BUY	$8.6 - $11.9 $8,703 - $12,042	1,012 Added 1.37%	74,977 $759,000
Q4 2023 Feb 08, 2024	BUY	$7.76 - $10.29 $11,174 - $14,817	1,440 Added 1.99%	73,965 $744,000
Q3 2023 Nov 09, 2023	BUY	$9.14 - $24.62 $48,304 - $130,116	5,285 Added 7.86%	72,525 $679,000
Q2 2023 Aug 07, 2023	SELL	$23.2 - $27.29 $18,699 - $21,995	-806 Reduced 1.18%	67,240 $1.65 Million
Q1 2023 May 01, 2023	BUY	$22.26 - $30.85 $379,199 - $525,529	17,035 Added 33.39%	68,046 $1.58 Million
Q4 2022 Feb 07, 2023	SELL	$19.96 - $28.22 $67,145 - $94,932	-3,364 Reduced 6.19%	51,011 $1.29 Million
Q3 2022 Oct 25, 2022	BUY	$18.26 - $31.1 $14,516 - $24,724	795 Added 1.48%	54,375 $1.05 Million
Q2 2022 Aug 08, 2022	BUY	$19.08 - $26.7 $1.02 Million - $1.43 Million	53,580 New	53,580 $1.37 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

Stay updated on Texas Permanent School Fund with notifications on news.